Answers are grounded in this paper and cite their sources.
We evaluated whether germline genomic risk complements prostate-specific antigen (PSA) for prostate cancer early detection. P-CARE integrates a 601-variant polygenic hazard score, family history, and genetic ancestry. Long-term outcomes and clinically significant prostate cancer (csPCa) detection on biopsy were assessed in the Million Veteran Program (MVP), with external validation in the Prostate Cancer Prevention Trial (PCPT). Among 428,512 MVP participants, high versus low P-CARE risk was associated with increased hazards of treatment (HR 3.32) and metastasis (HR 3.32). Among men whose baseline PSA was measured at ages 40-49 with PSA 1-3 ng/mL, 15-year treatment/metastasis probabilities were 2.6%, 4.5%, and 10.2% across increasing P-CARE risk groups. High P-CARE risk also predicted csPCa on biopsy (OR 2.96), while PRS PSA was inversely associated with outcomes. Findings were consistent in PCPT. Germline genomic risk complements measured PSA, supporting prospective evaluation of genetically informed screening strategies.
No takes yet. Share an insight, caveat, or question.
Karunamuni et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: